OCGN Ocugen Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OCGN

Price (delayed)

$1.32

Market cap

$339.67M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.26

Enterprise value

$307.15M

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier ...

Highlights
OCGN's revenue has soared by 143% from the previous quarter and by 143% YoY
Ocugen's gross profit has surged by 143% QoQ and by 143% YoY
OCGN's quick ratio has dropped by 52% since the previous quarter and by 28% year-on-year
The equity fell by 45% YoY and by 31% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://ocugen.com
Peers: OMER OMGA

Key stats

What are the main financial stats of OCGN
Market
Shares outstanding
257.33M
Market cap
$339.67M
Enterprise value
$307.15M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.35
Price to sales (P/S)
53.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
50.89
Earnings
Revenue
$6.04M
EBIT
-$63.08M
EBITDA
-$61.84M
Free cash flow
-$72.53M
Per share
EPS
-$0.26
Free cash flow per share
-$0.3
Book value per share
$0.16
Revenue per share
$0.02
TBVPS
$0.26
Balance sheet
Total assets
$64.55M
Total liabilities
$23.98M
Debt
$6.94M
Equity
$40.56M
Working capital
$25.88M
Liquidity
Debt to equity
0.17
Current ratio
2.51
Quick ratio
2.31
Net debt/EBITDA
0.53
Margins
EBITDA margin
-1,024.5%
Gross margin
100%
Net margin
-1,045%
Operating margin
-1,085.7%
Efficiency
Return on assets
-77.8%
Return on equity
-103%
Return on invested capital
-409.4%
Return on capital employed
-132.9%
Return on sales
-1,045%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OCGN stock price

How has the Ocugen stock price performed over time
Intraday
-5.04%
1 week
11.86%
1 month
-4.35%
1 year
95.15%
YTD
129.57%
QTD
-19.51%

Financial performance

How have Ocugen's revenue and profit performed over time
Revenue
$6.04M
Gross profit
$6.04M
Operating income
-$65.53M
Net income
-$63.08M
Gross margin
100%
Net margin
-1,045%
OCGN's revenue has soared by 143% from the previous quarter and by 143% YoY
Ocugen's gross profit has surged by 143% QoQ and by 143% YoY
The net margin has soared by 70% YoY and by 68% from the previous quarter
The company's operating margin has surged by 70% YoY and by 68% QoQ

Growth

What is Ocugen's growth rate over time

Valuation

What is Ocugen stock price valuation
P/E
N/A
P/B
8.35
P/S
53.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
50.89
The EPS has grown by 35% year-on-year and by 26% since the previous quarter
The equity fell by 45% YoY and by 31% QoQ
The price to book (P/B) is 27% more than the 5-year quarterly average of 6.6
OCGN's revenue has soared by 143% from the previous quarter and by 143% YoY
The price to sales (P/S) is 10% more than the last 4 quarters average of 48.5

Efficiency

How efficient is Ocugen business performance
The return on sales has surged by 70% year-on-year and by 68% since the previous quarter
The ROIC has soared by 61% YoY and by 30% from the previous quarter
OCGN's ROE is down by 23% year-on-year but it is up by 11% since the previous quarter
The return on assets has grown by 11% since the previous quarter but it has declined by 11% year-on-year

Dividends

What is OCGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OCGN.

Financial health

How did Ocugen financials performed over time
OCGN's total assets is 169% greater than its total liabilities
OCGN's quick ratio has dropped by 52% since the previous quarter and by 28% year-on-year
The current ratio has dropped by 51% since the previous quarter and by 27% year-on-year
The debt is 83% less than the equity
The debt to equity has surged by 89% year-on-year and by 55% since the previous quarter
The equity fell by 45% YoY and by 31% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.